TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $12.00 price target.
Sam Slutsky has given his Buy rating due to a combination of factors including TScan Therapeutics’ progress in their TCR-T cell therapy programs. The company has shown promising results in their Phase 1 hematological malignancy study, particularly with their TSC-100 and TSC-101 candidates, which demonstrated a significant reduction in relapse rates compared to the control group. This suggests a strong potential for durability and persistence of the therapy, which is a positive indicator for future trials and regulatory approval.
Additionally, TScan’s discovery of TSC-102, targeting CD45 epitopes, could potentially expand their addressable patient population, further enhancing their market potential. The company’s advancements in their solid tumor program, despite the challenges of working with sicker patients, and the expansion of their ImmunoBank to increase patient eligibility, also contribute to the positive outlook. These factors, combined with a solid financial position with over two years of cash runway, support the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCRX in relation to earlier this year.